These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1058 related articles for article (PubMed ID: 14719996)

  • 1. Pharmacotherapy of the ion transport defect in cystic fibrosis: role of purinergic receptor agonists and other potential therapeutics.
    Kunzelmann K; Mall M
    Am J Respir Med; 2003; 2(4):299-309. PubMed ID: 14719996
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacotherapy of the ion transport defect in cystic fibrosis.
    Kunzelmann K; Mall M
    Clin Exp Pharmacol Physiol; 2001 Nov; 28(11):857-67. PubMed ID: 11703384
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacologic modulation of salt and water in the airway epithelium in cystic fibrosis.
    Knowles MR; Olivier K; Noone P; Boucher RC
    Am J Respir Crit Care Med; 1995 Mar; 151(3 Pt 2):S65-9. PubMed ID: 7533608
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Ursodeoxycholic acid inhibits ENaC and Na/K pump activity to restore airway surface liquid height in cystic fibrosis bronchial epithelial cells.
    Mroz MS; Harvey BJ
    Steroids; 2019 Nov; 151():108461. PubMed ID: 31344409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacological approaches to correcting the ion transport defect in cystic fibrosis.
    Roomans GM
    Am J Respir Med; 2003; 2(5):413-31. PubMed ID: 14719993
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis lung disease.
    Moore PJ; Tarran R
    Expert Opin Ther Targets; 2018 Aug; 22(8):687-701. PubMed ID: 30028216
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Relationships between cystic fibrosis transmembrane conductance regulator, extracellular nucleotides and cystic fibrosis.
    Marcet B; Boeynaems JM
    Pharmacol Ther; 2006 Dec; 112(3):719-32. PubMed ID: 16828872
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological treatment of the ion transport defect in cystic fibrosis.
    Roomans GM
    Expert Opin Investig Drugs; 2001 Jan; 10(1):1-19. PubMed ID: 11116277
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adenosine receptors, cystic fibrosis, and airway hydration.
    Com G; Clancy JP
    Handb Exp Pharmacol; 2009; (193):363-81. PubMed ID: 19639288
    [TBL] [Abstract][Full Text] [Related]  

  • 10. TMEM16A Potentiation: A Novel Therapeutic Approach for the Treatment of Cystic Fibrosis.
    Danahay HL; Lilley S; Fox R; Charlton H; Sabater J; Button B; McCarthy C; Collingwood SP; Gosling M
    Am J Respir Crit Care Med; 2020 Apr; 201(8):946-954. PubMed ID: 31898911
    [No Abstract]   [Full Text] [Related]  

  • 11. Epithelial sodium channel silencing as a strategy to correct the airway surface fluid deficit in cystic fibrosis.
    Gianotti A; Melani R; Caci E; Sondo E; Ravazzolo R; Galietta LJ; Zegarra-Moran O
    Am J Respir Cell Mol Biol; 2013 Sep; 49(3):445-52. PubMed ID: 23600628
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ion channels as targets to treat cystic fibrosis lung disease.
    Martin SL; Saint-Criq V; Hwang TC; Csanády L
    J Cyst Fibros; 2018 Mar; 17(2S):S22-S27. PubMed ID: 29102290
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mathematical model reveals role of nucleotide signaling in airway surface liquid homeostasis and its dysregulation in cystic fibrosis.
    Sandefur CI; Boucher RC; Elston TC
    Proc Natl Acad Sci U S A; 2017 Aug; 114(35):E7272-E7281. PubMed ID: 28808008
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Resveratrol ameliorates abnormalities of fluid and electrolyte secretion in a hypoxia-Induced model of acquired CFTR deficiency.
    Woodworth BA
    Laryngoscope; 2015 Oct; 125 Suppl 7(0 7):S1-S13. PubMed ID: 25946147
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Extracellular zinc and ATP restore chloride secretion across cystic fibrosis airway epithelia by triggering calcium entry.
    Zsembery A; Fortenberry JA; Liang L; Bebok Z; Tucker TA; Boyce AT; Braunstein GM; Welty E; Bell PD; Sorscher EJ; Clancy JP; Schwiebert EM
    J Biol Chem; 2004 Mar; 279(11):10720-9. PubMed ID: 14701827
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cystic fibrosis airway epithelial Ca2+ i signaling: the mechanism for the larger agonist-mediated Ca2+ i signals in human cystic fibrosis airway epithelia.
    Ribeiro CM; Paradiso AM; Carew MA; Shears SB; Boucher RC
    J Biol Chem; 2005 Mar; 280(11):10202-9. PubMed ID: 15647273
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Resveratrol and ivacaftor are additive G551D CFTR-channel potentiators: therapeutic implications for cystic fibrosis sinus disease.
    Cho DY; Zhang S; Lazrak A; Grayson JW; Peña Garcia JA; Skinner DF; Lim DJ; Mackey C; Banks C; Matalon S; Woodworth BA
    Int Forum Allergy Rhinol; 2019 Jan; 9(1):100-105. PubMed ID: 30152192
    [TBL] [Abstract][Full Text] [Related]  

  • 18. ENaC inhibitors and airway re-hydration in cystic fibrosis: state of the art.
    Althaus M
    Curr Mol Pharmacol; 2013 Mar; 6(1):3-12. PubMed ID: 23547930
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The epithelial sodium channel (ENaC) as a therapeutic target for cystic fibrosis.
    Shei RJ; Peabody JE; Kaza N; Rowe SM
    Curr Opin Pharmacol; 2018 Dec; 43():152-165. PubMed ID: 30340955
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [CFTR and transepithelial ionic transport abnormalities in cystic fibrosis].
    Becq F
    Arch Pediatr; 2003 Sep; 10 Suppl 2():325s-332s. PubMed ID: 14671929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 53.